Research programme: RNA interference-based technology - Alnylam

Drug Profile

Research programme: RNA interference-based technology - Alnylam

Alternative Names: KC2; MC3; MC3 LNP; MD1; reLNP

Latest Information Update: 14 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer AlCana Technologies; Alnylam Pharmaceuticals; Icahn School of Medicine at Mount Sinai; Massachusetts General Hospital; Massachusetts Institute of Technology; University of Bonn; University of British Columbia
  • Class Small interfering RNA
  • Mechanism of Action CCR2 receptor antagonists; Claudin 3 inhibitors; DNA-directed RNA polymerase inhibitors; RNA interference; TOR1A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Dystonia; Inflammation; Influenza A virus infections

Most Recent Events

  • 17 Jan 2013 No development reported - Preclinical for Cancer in Germany (Parenteral)
  • 16 Jan 2013 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top